Felix Knauf, MD
Assistant Professor of Internal Medicine (Adjunct)About
Research
Publications
2024
Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients
Hardenberg J, Kunz J, Rubarth K, Mittermaier M, Pigorsch M, Balzer F, Witzenrath M, Hinz R, Körner R, Eckardt K, Knauf F, Hinrichs C, Enghard P. Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients. Clinical Kidney Journal 2024, sfae328. DOI: 10.1093/ckj/sfae328.Peer-Reviewed Original ResearchGlucose 5% solutionGlucose 5%Severe hypernatremiaDrug diluentDrug solventSodium concentrationAssociated with increased mortalityResults Baseline characteristicsAdult COVID-19 patientsRetrospective before-and-after studyCritically ill patientsIntensive care unitPre-emptive usePrevalence of hypernatremiaStudy intensive care unitVenous blood gasesLength of stayCOVID-19 patientsBaseline characteristicsClinical outcomesICU admissionHypernatremiaMedical ICUCare unitBlood gasesOpportunities in primary and enteric hyperoxaluria at the cross-roads between the clinic and laboratory
Cellini B, Baum M, Frishberg Y, Groothoff J, Harris P, Hulton S, Knauf F, Knight J, Lieske J, Lowther W, Moochhala S, Nazzal, Tasian G, Whittamore J, Sas D. Opportunities in primary and enteric hyperoxaluria at the cross-roads between the clinic and laboratory. Kidney International Reports 2024, 9: 3083-3096. DOI: 10.1016/j.ekir.2024.08.031.Peer-Reviewed Original ResearchPrimäre Hyperoxalurie
Saadé C, Knauf F. Primäre Hyperoxalurie. Nephrologie Aktuell 2024, 28: 272-278. DOI: 10.1055/a-2270-5042.Peer-Reviewed Original ResearchRecovery From Severe Heart Failure in a Patient With Primary Hyperoxaluria Type 1 After Treatment With Lumasiran, Pyridoxine, and Kidney Transplant
Choi M, Kahl A, Hawkins-van der Cingel G, Noriega M, Klingel K, Doeblin P, Schoenrath F, Eckardt K, Öllinger R, Knauf F, Halleck F. Recovery From Severe Heart Failure in a Patient With Primary Hyperoxaluria Type 1 After Treatment With Lumasiran, Pyridoxine, and Kidney Transplant. Annals Of Internal Medicine Clinical Cases 2024, 3 DOI: 10.7326/aimcc.2023.1428.Peer-Reviewed Original ResearchOxalate Metabolism: From Kidney Stones to Cardiovascular Disease
Hawkins-van der Cingel G, Walsh S, Eckardt K, Knauf F. Oxalate Metabolism: From Kidney Stones to Cardiovascular Disease. Mayo Clinic Proceedings 2024, 99: 1149-1161. PMID: 38762815, DOI: 10.1016/j.mayocp.2024.02.006.Peer-Reviewed Original ResearchInterleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individuals
2023
Design Research to Embed mHealth into a Community-Led Blood Pressure Management System in Uganda: Protocol for a Mixed Methods Study
Schwab J, Wachinger J, Munana R, Nabiryo M, Sekitoleko I, Cazier J, Ingenhoff R, Favaretti C, Pillai V, Weswa I, Wafula J, Emmrich J, Bärnighausen T, Knauf F, Knauss S, Nalwadda C, Sudharsanan N, Kalyesubula R, McMahon S. Design Research to Embed mHealth into a Community-Led Blood Pressure Management System in Uganda: Protocol for a Mixed Methods Study. JMIR Research Protocols 2023, 12: e46614. PMID: 38032702, PMCID: PMC10722357, DOI: 10.2196/46614.Peer-Reviewed Original ResearchINTERNATIONAL REGISTERED REPORT IDENTIFIERIntervention prototypeManagement of hypertensionHealth careChronic disease managementMixed-methods studyMobile health interventionsResource-constrained settingsHealth system challengesUncontrolled hypertensionAntihypertensive medicationsGerman RegistryHypertension managementRisk factorsClinical trialsCardiovascular diseaseHypertensionMethods studyBasic health careMedicationsHealth interventionsConcurrent trialsSuch diseasesDisease managementPrivate facilitiesChallenges to Implementation of Community Health Worker-Led Chronic Obstructive Pulmonary Disease (COPD) Screening and Referral in Rural Uganda: A Qualitative Study using the Implementation Outcomes Framework
Ingenhoff R, Robertson N, Munana R, Bodnar B, Weswa I, Sekitoleko I, Gaal J, Kirenga B, Kalyesubula R, Knauf F, Siddharthan T. Challenges to Implementation of Community Health Worker-Led Chronic Obstructive Pulmonary Disease (COPD) Screening and Referral in Rural Uganda: A Qualitative Study using the Implementation Outcomes Framework. International Journal Of Chronic Obstructive Pulmonary Disease 2023, 18: 2769-2783. PMID: 38046984, PMCID: PMC10693197, DOI: 10.2147/copd.s420137.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseImplementation Outcomes FrameworkCOPD screeningRural UgandaBurden of COPDReferral processCommunity health worker interventionHealth worker interventionObstructive pulmonary diseaseHealthcare providers' perceptionsCause of deathHigh patient volumeCommunity-based interventionsCHW supportCOPD awarenessCOPD careMiddle-income countriesPulmonary diseaseMedication accessBody of evidenceOutcomes FrameworkQualitative studyHealth outcomesProviders' perceptionsPatient volumeSLC26A6 Plays a Major Role in Release of Soluble Oxalate from Macrophages Following Internalization of Calcium Oxalate Crystals
Najenson A, Wagner T, Bachmann S, Thomson R, Knauf F, Aronson P. SLC26A6 Plays a Major Role in Release of Soluble Oxalate from Macrophages Following Internalization of Calcium Oxalate Crystals. Journal Of The American Society Of Nephrology 2023, 34: 490-490. DOI: 10.1681/asn.20233411s1490b.Peer-Reviewed Original ResearchHeart Failure Recovery After Lumasiran and Isolated Kidney Transplantation in Primary Hyperoxaluria Type 1
der Cingel G, Choi M, Kahl A, Schoenrath F, Rehse G, Eckardt K, Knauf F, Halleck F. Heart Failure Recovery After Lumasiran and Isolated Kidney Transplantation in Primary Hyperoxaluria Type 1. Journal Of The American Society Of Nephrology 2023, 34: 565-565. DOI: 10.1681/asn.20233411s1565d.Peer-Reviewed Original Research